Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
American Journal of Epidemiology · 2024
DOI: 10.1093/aje/kwae137 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2024. Verfasst von Paris J Baptiste und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, GlaxoSmithKline.
Abstract (Originalsprache)
Cardiovascular disease is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial), each prevent cardiovascular disease. However, trial results may not be generalizable, and their effectiveness in underrepresented groups is unclear. Using trial emulation methods within routine-care data to validate findings, we explored the generalizability of ONTARGET results. For people prescribed an ACEi/ARB in the UK Clinical Practice Research Datalink GOLD dataset from January 1, 2001, to July 31, 2019, we applied trial criteria and propensity-score methods to create an ONTARGET trial-eligible cohort. Comparing ARB with ACEi, we estimated hazard ratios for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure) and secondary outcomes. Because the prespecified criteria were met, confirming trial emulation, we then explored treatment heterogeneity among 3 trial-underrepresented subgroups: females, persons aged ≥75 years, and those with chronic kidney disease. In the trial-eligible population (n = 137 155), results for the primary outcome demonstrated similar effects of ARB and ACEi (hazard ratio = 0.97; 95% CI, 0.93-1.01), meeting the prespecified validation criteria. When extending this outcome to trial-underrepresented groups, similar treatment effects were observed by sex, age, and chronic kidney disease. This suggests that ONTARGET trial findings are generalizable to trial-underrepresented subgroups. This article is part of a Special Collection on Pharmacoepidemiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.
- Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London E1 4NS, United Kingdom.
- Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada.
- Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.
- Department of Medicine 4, Faculty of Medicine, Friedrich Alexander University, 91054 Erlangen, Germany.
ORCID-Profile: Paris J Baptiste, Angel Y S Wong, Anna Schultze, Catherine M Clase, Clémence Leyrat, Elizabeth Williamson, Emma Powell, Johannes F E Mann, Marianne Cunnington, Koon Teo, Shrikant I Bangdiwala, Laurie Tomlinson, Kevin Wing
Förderung
- Wellcome Trust
- GlaxoSmithKline
Zitieren
APA
Baptiste, P. J., Wong, A. Y. S., Schultze, A., Clase, C. M., Leyrat, C., Williamson, E., Powell, E., Mann, J. F. E., Cunnington, M., Teo, K., Bangdiwala, S. I., Gao, P., Tomlinson, L., & Wing, K. (2024). Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae137
Vancouver
Baptiste PJ, Wong AYS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). American Journal of Epidemiology. 2024. doi:10.1093/aje/kwae137
BibTeX
@article{Baptiste2024,
author = {Baptiste, Paris J and Wong, Angel Y S and Schultze, Anna and Clase, Catherine M and Leyrat, Clémence and Williamson, Elizabeth and Powell, Emma and Mann, Johannes F E and Cunnington, Marianne and Teo, Koon and Bangdiwala, Shrikant I and Gao, Peggy and Tomlinson, Laurie and Wing, Kevin},
title = {Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)},
journal = {American Journal of Epidemiology},
year = {2024},
doi = {10.1093/aje/kwae137}
}
EUVIMED